In an interview with <em>Targeted Oncology</em>, Katherine A. McGlynn, PhD, MPH, discussed the population attributable fraction of non-alcoholic fatty liver disease in developing hepatocellular carcinoma, as well as related disorders, in the United States that contribute to the risk of mortality.<br />
In an interview with <em>Targeted Oncology</em>, Neil P. Shah, MD, PhD, discussed the latest advancements in the treatment landscape of chronic myeloid leukemia, including the introduction of tyrosine kinase inhibitors. He also addressed some of the challenges both oncologists and patients face in this space.<br />
In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, discussed what he’s looking forward to at the 2019 ISGIO Annual Conference and why this meeting is so important to physicians in the field of GI oncology. He also highlighted the surgical approaches to treating patients with HCC from his own experiences as a surgical oncologist, as well as the challenges associated with these treatment options.
In an interview with <em>Targeted Oncology</em>, Raymond L. Chai, MD, discussed the latest treatment advancements for thyroid cancer that he has seen over the past few years and how he sees quality of life improving for patients with advanced subtypes of thyroid cancer. He also shared a personal message for oncologists in honor of Thyroid Cancer Awareness Month.
In an interview with Targeted Oncology, Charles Geyer, MD, discussed the potential role of neratinib as well as other new agents that are coming down the pipeline for the treatment of patients with metastatic HER2-positive breast cancer. He also addressed the biggest challenges oncologists face in managing this disease.
In an interview with Targeted Oncology, Florencia McAllister, MD, discussed the data from these analyses of the tumor microbiome in patients with pancreatic cancer and their potential significance. She also discussed the next steps necessary for validating these results.
In a recent analysis published in <em>JAMA</em>, data were evaluated from a collection of clinical trials and analyzed for important takeaways in the testing and treatment of patients with non–small cell lung cancer. The authors stress the importance of molecular testing in patients with NSCLC as more targeted therapies become available. <br />
In an interview with Targeted Oncology, Muhammed Murtaza, MBBS, PhD, discussed the role for TARDIS in the treatment landscape of early-stage breast cancer, as well as the data supporting its use. He also highlighted next steps necessary for validating these results and the potential clinical value of liquid biopsies in the breast cancer space.
In an interview with Targeted Oncology, Matthew S. Ning, MD, MPH, discussed the role for low-dose radiotherapy as treatment of patients with relapsed/refractory MCL, according to the findings from a recent analysis. He also highlighted how a multidisciplinary approach can impact the treatment of patients with MCL.
Here's a look back on the FDA happenings for the month of August 2019, including FDA approvals, priority reviews, and breakthrough designations.
In an interview with Targeted Oncology, Shailender Bhatia, MD, highlighted the key takeaways from the 5 abstracts he found most significant at the 2019 ASCO meeting for the treatment of patients with melanoma.
In an interview with Targeted Oncology, Evert F.S. van Velsen, MD, MSc, discussed the evaluation of the 2015 ATA Risk Stratification in patients with DTC, including patients with PTC and FTC. He also highlighted challenges in treating patients that have been defined as high-risk for recurrence.
In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.
Findings from a phase II study in patients with small cell lung cancer suggested tumor immune phenotypes can be predictive of response to immune checkpoint blockade. Responses to the combination of durvalumab plus olaparib were observed in all patients where tumors had an inflamed phenotype.
In an interview with Targeted Oncology, Martin E. Gutierrez, MD, discussed the findings from the first-in-human phase I study investigating H3B-6527 in patients with HCC and ICC. He also highlighted the potential role for combination therapy with H3B-6527 and the next steps planned for subsequent phase II and III trials in HCC and ICC.
John L. Marshall, MD, spoke with a group of physicians during a Targeted Oncology live case-based peer perspectives discussion on the different classes of agents available to treat patients with gastrointestinal cancers.
In an interview with <em>Targeted Oncology</em>, Ruben Mesa, MD, discussed the results from the reanalysis of the JAKARTA-2 trial that led to the approval of fedratinib in patients with MF. He also highlighted the role of the FREEDOM study that is currently enrolling patients with MF for treatment with fedratinib.
In an interview with Targeted Oncology, Alessandra Tedeschi, MD, discussed the 5-year data she presented at the 2019 EHA Meeting for frontline ibrutinib as a treatment for patients with CLL. She also highlighted other research that may also benefit elderly patients with CLL, including the emerging combination of venetoclax and obinutuzumab.
Krishnansu S. Tewari, MD, discussed the results from the phase III clinical trial investigating the addition of bevacizumab to standard chemotherapy treatment following surgery in patients with advanced ovarian cancer, and the next steps for research regarding the role of bevacizumab in ovarian cancer treatment.
In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
Next-generation sequencing has increasingly become more valuable to physicians treating cancer at academic medical centers, but these tests also need to be incorporated more into community oncology practices. A recent study, presented at the 2019 ASCO Annual Meeting, demonstrated that the use of these tests has increased in the community setting as the technology, and the use and approval of matched therapies, continues to develop.
With 5 tyrosine kinase inhibitors approved for the treatment of patients with hepatocellular carcinoma, the next step for research in this treatment paradigm is focused on identifying the appropriate sequence of these agents.
Olaparib improved progression-free survival compared to placebo in patients with <em>BRCA</em>-mutant metastatic pancreatic cancer, based on data from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.
Take a look back on the FDA happenings, including approvals, fast track designations, priority reviews, and more from the month of July 2019.
Vivek Subbiah, MD, discussed the activity and tolerability of BLU-667 in patients with advanced <em>RET</em>-altered MTC and PTC. He also discussed the next steps planned for this ongoing trial and how this agent can impact the treatment landscape of patients with <em>RET</em>-altered thyroid cancers.
In an interview with Targeted Oncology, Naveen Pemmaraju, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discussed the safety of SL-401 as a treatment in patients with MF following relapse or intolerance to JAK inhibition, based on data from an ongoing phase I/II clinical trial. He highlighted other research that also appear promising for this subgroup of patients with a poor prognosis.
In an interview with Targeted Oncology, Rodabe N. Amaria, MD, discussed the guidelines and recommendations outlined by the INMC. She also highlighted the importance of genomic testing in the neoadjuvant setting of melanoma.
In an interview with Targeted Oncology, Richard M. Stone, MD, discussed the biggest controversies across a number of patient populations in AML. He also highlighted some areas of research he finds particularly exciting for the treatment of patients with AML.
In an interview with Targeted Oncology, Arlene Siefker-Radtke, MD, discussed the results from this trial that led to the approval of erdafitinib in patients with locally advanced or metastatic bladder cancer who have progressed on platinum-based chemotherapy. She also explained the impact of this approval in this patient population and next steps planned for this agent.
In an interview with <em>Targeted Oncology</em>, David Polsky, MD, PhD, discussed the findings from this analysis in patients with <em>BRAF</em>-mutant, unresectable, metastatic melanoma. He highlighted the next steps necessary for validating these findings and potentially using ctDNA to help inform treatment decisions for patients with metastatic melanoma.